Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management.
By E. Yeh, Courtney L. Bickford. Journal of the American College of Cardiology, 2009
1,235 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Oncology
View Paper: https://www.semanticscholar.org/paper/a2fee6387a646980fb2b16df7b238064aba5bdc6
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
Citations in the corpus
- Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management (2016, background): “Conventional chemotherapeutics, such as anthracyclines, antimetabolites, and cyclophosphamide, can induce permanent myocardial cell injury, leading to acute or chronic LVD.(21,22) Anthracyclines, commonly used in the treatment of solid tumors (ie, breast cancer, osteosarcoma, etc) and hematologic ma”
- Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy (2015, neutral): “001 Breast cancer 131 (58) 1213 (51) Hodgkin’s disease 10 (4) 113 (5) Non-Hodgkin’s lymphoma 46 (20) 695 (29) Myeloma 8 (4) 144 (6) Ovarian 2 (1) 67 (3) Other hematoncologic diseases 10 (4) 76 (3) Other solid tumors 19 (8) 91 (4) Cumulative anthracycline dose, ‡§ mg/mq 359 172 299 144 <0.”
- Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. (2013, neutral): “Sequential measurement of ejection fraction (EF) is used in a variety of conditions, perhaps most commonly in the assessment of potential cardiotoxicity from chemotherapy or immune therapy in patients with malignancies (1).”
- Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. (2014, background): “Many of the chemotherapeutic agents in use today can have associated cardiovascular side effects, the most common of which are cardiomyopathy and HF (45,60).”
- Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. (2014, methodology): “Stress echocardiography, an established technique for the detection and prognostication of stable CAD as recommended by guidelines, may be useful in the evaluation of patients with intermediate or high pre-test probability for CAD (uninterpretable electrocardiogram or unable to exercise),(131) who a”
- 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). (2016, background): “Arrhythmias can be present at baseline in 16–36% of treated patients with cancer.(11,150) 2.”
- Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. (2014, background): “high pretest probability for CAD (uninterpretable electrocardiogram or unable to exercise),(131) who are undergoing regimens that may be associated with ischemia (fluorouracil, bevacizumab, sorafenib, and sunitinib).(132) In addition, there are two specific areas in which stress echocardiography may”
- Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. (2014, neutral): “Anthracycline-induced cardiomyopathy has been classified as early or late onset using a cutoff of 1 year after anthracycline treatment (10).”